文献速递中医内科中药与中成药合理使用

中成药联合奥司他韦治疗成人流感的疗效与安全性:系统评价与Meta分析

Clinical Efficacy and Safety of Chinese Patent Medicine Combined with Oseltamivir for the Treatment of Adult Influenza: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Chin Med · 2022-04-26

该系统评价检索多个数据库至2021年6月,纳入9项随机对照试验共906例成人流感患者,比较中成药联合奥司他韦与单用奥司他韦的疗效与安全性。Meta分析显示联合治疗在退热时间、症状改善时间和住院时间上均优于单用奥司他韦,不良反应较少但无统计学差异。结论认为联合治疗可缩短退热和症状改善时间及住院时间,但研究方法学质量较低,需大样本多中心试验进一步验证。

要点

  • 中成药联合奥司他韦可缩短成人流感退热时间、症状改善时间和住院时间。
  • 联合治疗不良反应发生率低于单用奥司他韦,但差异无统计学意义。
  • 纳入研究的方法学质量较低,结论需谨慎解读并待高质量试验验证。

核心结论

  • 中成药联合奥司他韦治疗成人流感在缩短退热时间、症状改善时间和住院时间方面优于单用奥司他韦。
  • 联合治疗组不良反应少于对照组,但差异无统计学意义(RR=0.69,95%CI 0.38–1.23,P=0.21)。
  • 由于纳入研究方法学质量较低且文献数量少,结论需进一步大样本多中心临床试验验证。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Embase、Cochrane Library、SinoMed、CNKI和Wanfang数据库至2021年6月1日。
  • 纳入9项随机对照试验,共906例成人流感患者。
  • 采用Review Manager 5.2进行数据分析与偏倚风险评估。

主要发现

  • 与单用奥司他韦相比,中成药联合奥司他韦的退热时间缩短(MD=-17.68,95%CI -25.93至-9.44,P<0.0001)。
  • 症状改善时间缩短(MD=-22.28,95%CI -26.77至-17.80,P<0.00001)。
  • 住院时间缩短(MD=-2.04,95%CI -3.45至-0.63,P=0.005)。
  • 不良反应方面,联合组少于对照组,但无统计学意义(RR=0.69,95%CI 0.38–1.23,P=0.21)。

临床怎么用

  • 成人流感患者可在奥司他韦基础上联合中成药,以缩短退热、症状改善和住院时间。
  • 联合用药时需关注不良反应,尽管本研究中联合组不良反应较少但无统计学差异。
  • 临床决策应结合患者具体情况,并注意现有证据的方法学局限性。

局限性

  • 纳入研究的方法学质量较低,诊断标准和成人流感定义存在差异。
  • 纳入文献数量少,可能存在发表偏倚。
  • 需要大样本、多中心临床试验进一步验证疗效与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Influenza is a sudden and serious viral breathing and lung-related infectious disease that causes significant deadliness and death worldwide. Now, the international treatment is oseltamivir. Chinese patent medicine (CPM) as a kind of different therapy is used in the treatment of influenza in China. The aim of this study was to interpret the clinical efficacy and safety of CPM combined with oseltamivir in the treatment of adult influenza by reviewing all relevant randomized controlled trials, and to provide new ideas and methods for the treatment of influenza. PubMed, Embase, Cochrane Library, SinoMed, CNKI, and Wanfang Database were searched from the date of beginning until 1 June 2021, for the references on treatment of influenza with CPM. According to standard information extraction tables, two people worked to find and aggregate information independently. Review Manager 5.2 was used to study data carefully and evaluate risk of bias. A total of nine trials of 906 patients were included. Based on the meta-analysis, compared to oseltamivir, CPM combined with oseltamivir had better effect in the time of defervescence [MD = -17.68, 95% CI (-25.93, -9.44), P < 0.0001], the time of symptom improvement [MD = -22.28, 95% CI (-26.77, -17.80), P < 0.00001], and the time of hospitalization [MD = -2.04, 95% CI (-3.45, -0.63), P = 0.005]. Related to safety [RR = 0.69, 95% CI (0.38, 1.23), P = 0.21], the experimental group had fewer adverse reactions than the control group, but there is no statistical significance. The findings show that CPM combined with oseltamivir in adult influenza has a better efficacy in shortening the time of defervescence and symptom improvement, reducing the time of hospitalization. However, publication bias is inevitable due to the low methodological quality check of the clinical research about diagnostic criteria, definition of adult influenza, and small number of articles, and further large sample sizes and multi-center clinical trials are needed to give better proof for its efficacy and safety.

来源:Am J Chin Med,查看原文。版权归原作者所有。

引用

  1. Li X, Liu B, Duan N, et al. Clinical Efficacy and Safety of Chinese Patent Medicine Combined with Oseltamivir for the Treatment of Adult Influenza: A Systematic Review and Meta-Analysis. Am J Chin Med. 2022. PMID: 35475973. doi:10.1142/S0192415X22500422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。